Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Open-market sale President and CEO sold 6,500 shares at $20.05 ($130,325)
  2. 4 Open-market sale Chief Financial Officer sold 3,040 shares at an average $21.09 ($64,111)
  3. 4 Open-market sale Chief Medical Officer sold 15,000 shares at $18.66 ($279,900)
  4. 4 Open-market sale President and CEO sold 6,500 shares at $18.66 ($121,290)
  5. 4 Open-market sale Chief Financial Officer sold 3,100 shares at $19.81 ($61,411)
  6. 4 Open-market sale Chief Medical Officer sold 15,000 shares at an average $19.68 ($295,157)
  7. 4 Open-market sale President and CEO sold 6,500 shares at an average $19.68 ($127,902)
  8. 4 Open-market sale Chief Financial Officer sold 3,100 shares at $18.75 ($58,125)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Open-market sale Director sold 8,599 shares at $19.04 ($163,725)
  17. 4 Open-market sale Chief Financial Officer sold 3,100 shares at $19.07 ($59,117)
  18. 4 Open-market sale Director sold 10,000 shares at $18.35 ($183,500)
  19. 4 Open-market sale Director sold 30,000 shares at an average $22.26 ($667,736)
  20. 4 Open-market sale President and CEO sold 15,440 shares at an average $20.98 ($323,955)

Page 18 of 22 · 435 filings